Ischemic Heart Disease (D Mukherjee, Section Editor)

Current Cardiology Reports

, 15:369

First online:

Stem Cell Therapy for Pediatric Dilated Cardiomyopathy

  • Sarah M. SelemAffiliated withInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
  • , Sunjay KaushalAffiliated withDivision of Cardiac Surgery, University of Maryland Medical Center
  • , Joshua M. HareAffiliated withInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Dilated cardiomyopathy is a serious and life-threatening disorder in children. It is the most common form of pediatric cardiomyopathy. Therapy for this condition has varied little over the last several decades and mortality continues to be high. Currently, children with dilated cardiomyopathy are treated with pharmacological agents and mechanical support, but most require heart transplantation and survival rates are not optimal. The lack of common treatment guidelines and inadequate survival rates after transplantation necessitates more therapeutic clinical trials. Stem cell and cell-based therapies offer an innovative approach to restore cardiac structure and function towards normal, possibly reducing the need for aggressive therapies and cardiac transplantation. Mesenchymal stem cells and cardiac stem cells may be the most promising cell types for treating children with dilated cardiomyopathy. The medical community must begin a systematic investigation of the benefits of current and novel treatments such as stem cell therapies for treating pediatric dilated cardiomyopathy.


Pediatric dilated cardiomyopathy Idiopathic dilated cardiomyopathy Pediatric congestive heart failure Stem cells Cell based therapy Bone marrow stem cells Mesenchymal stem cells Cardiac stem cells